Bio-Rad Laboratories, Inc.
BIO
$279.03
-$5.65-1.99%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 759.90M | -675.90M | 319.20M | -2.16B | -1.84B |
| Total Depreciation and Amortization | 165.40M | 162.10M | 156.80M | 152.60M | 151.60M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -665.50M | 1.20B | -67.20M | 3.16B | 2.77B |
| Change in Net Operating Assets | 272.40M | -197.70M | 125.40M | -631.20M | -620.80M |
| Cash from Operations | 532.20M | 491.50M | 534.20M | 515.30M | 455.20M |
| Capital Expenditure | -157.60M | -154.70M | -163.20M | -159.80M | -165.60M |
| Sale of Property, Plant, and Equipment | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K |
| Cash Acquisitions | -218.50M | -218.50M | -216.70M | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 186.30M | 187.10M | 181.10M | 45.50M | 5.30M |
| Cash from Investing | -189.70M | -186.00M | -198.70M | -114.20M | -160.20M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -500.00K | -300.00K | -400.00K | -300.00K | -400.00K |
| Issuance of Common Stock | 15.80M | 15.80M | 17.50M | 18.00M | 19.20M |
| Repurchase of Common Stock | -298.50M | -298.20M | -343.30M | -304.20M | -207.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -30.00M | -30.00M | -30.00M | -30.60M |
| Cash from Financing | -283.20M | -312.70M | -356.20M | -316.50M | -218.80M |
| Foreign Exchange rate Adjustments | -16.90M | -6.80M | -15.30M | 4.70M | 9.20M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 42.40M | -14.00M | -36.00M | 89.30M | 85.40M |